• Junshi Biosciences announced Oct. 28, 2026, that China’s NMPA accepted a supplemental application for subcutaneous toripalimab combined with disitamab vedotin.
• The combination targets first-line treatment of HER2-expressing locally advanced or metastatic urothelial carcinoma.
• Applications for the subcutaneous formulation now cover all 13 indications approved for intravenous toripalimab.
• Phase 3 results in first-line non-squamous non-small cell lung cancer were presented at the European Lung Cancer Congress in March 2026.
• The chemotherapy-combination study showed non-inferior drug exposure versus intravenous toripalimab, with comparable efficacy and safety.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Shanghai Junshi Biosciences Co. Ltd. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202610282025PRIMZONEFULLFEED9855772) on October 29, 2026, and is solely responsible for the information contained therein.